BIOMAT Database Logo BIOMAT Database Logo

Decreased blood pressure in response to an angiotensin II antagonist in Addison's disease. 1979

T Ogihara, and T Hata, and M Nakamaru, and H Mikami, and A Maruyama, and Y Oakada, and Y Kumahara

The synthetic angiotensin II antagonist, 1-sarcosine, 8-isoleucine angiotensin II was infused in two patients with untreated Addison's disease. Blood pressure decreased following infusion of this angiotensin II antagonist. Re-infusion of the antagonist after cortisol replacement therapy for one month caused a slight increase in blood pressure. Addison's disease is one of the conditions in which the renin-angiotensin system is involved in the maintenance of blood pressure.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006854 Hydrocortisone The main glucocorticoid secreted by the ADRENAL CORTEX. Its synthetic counterpart is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Cortef,Cortisol,Pregn-4-ene-3,20-dione, 11,17,21-trihydroxy-, (11beta)-,11-Epicortisol,Cortifair,Cortril,Epicortisol,Hydrocortisone, (11 alpha)-Isomer,Hydrocortisone, (9 beta,10 alpha,11 alpha)-Isomer,11 Epicortisol
D000224 Addison Disease An adrenal disease characterized by the progressive destruction of the ADRENAL CORTEX, resulting in insufficient production of ALDOSTERONE and HYDROCORTISONE. Clinical symptoms include ANOREXIA; NAUSEA; WEIGHT LOSS; MUSCLE WEAKNESS; and HYPERPIGMENTATION of the SKIN due to increase in circulating levels of ACTH precursor hormone which stimulates MELANOCYTES. Addison's Disease,Primary Adrenal Insufficiency,Primary Adrenocortical Insufficiency,Primary Hypoadrenalism,Addisons Disease,Adrenal Insufficiency, Primary,Adrenocortical Insufficiencies, Primary,Adrenocortical Insufficiency, Primary,Disease, Addison,Hypoadrenalism, Primary,Hypoadrenalisms, Primary,Insufficiencies, Primary Adrenocortical,Insufficiency, Primary Adrenocortical,Primary Adrenocortical Insufficiencies
D000804 Angiotensin II An octapeptide that is a potent but labile vasoconstrictor. It is produced from angiotensin I after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME. The amino acid in position 5 varies in different species. To block VASOCONSTRICTION and HYPERTENSION effect of angiotensin II, patients are often treated with ACE INHIBITORS or with ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS. Angiotensin II, Ile(5)-,Angiotensin II, Val(5)-,5-L-Isoleucine Angiotensin II,ANG-(1-8)Octapeptide,Angiotensin II, Isoleucine(5)-,Angiotensin II, Valine(5)-,Angiotensin-(1-8) Octapeptide,Isoleucine(5)-Angiotensin,Isoleucyl(5)-Angiotensin II,Valyl(5)-Angiotensin II,5 L Isoleucine Angiotensin II,Angiotensin II, 5-L-Isoleucine

Related Publications

T Ogihara, and T Hata, and M Nakamaru, and H Mikami, and A Maruyama, and Y Oakada, and Y Kumahara
SC-52458, an orally active angiotensin II-receptor antagonist: inhibition of blood pressure response to angiotensin II challenges and pharmacokinetics in normal volunteers.
April 1997, Journal of cardiovascular pharmacology,
T Ogihara, and T Hata, and M Nakamaru, and H Mikami, and A Maruyama, and Y Oakada, and Y Kumahara
Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients.
October 2001, Journal of hypertension,
T Ogihara, and T Hata, and M Nakamaru, and H Mikami, and A Maruyama, and Y Oakada, and Y Kumahara
Cerebroventricular injection of angiotensin II antagonist: effects on blood pressure responses to central and systemic angiotensin II.
May 1995, The Journal of pharmacology and experimental therapeutics,
T Ogihara, and T Hata, and M Nakamaru, and H Mikami, and A Maruyama, and Y Oakada, and Y Kumahara
[Decreased response of the blood pressure to synthetic angiotensin II in rats with CCl-4-induced liver cirrhosis].
January 1967, Medicina et pharmacologia experimentalis. International journal of experimental medicine,
T Ogihara, and T Hata, and M Nakamaru, and H Mikami, and A Maruyama, and Y Oakada, and Y Kumahara
Blood pressure response to the portal infusion of angiotensin-II.
January 1966, Surgical forum,
T Ogihara, and T Hata, and M Nakamaru, and H Mikami, and A Maruyama, and Y Oakada, and Y Kumahara
Enhancement of blood pressure response to dopamine by angiotensin II.
January 1981, Hypertension (Dallas, Tex. : 1979),
T Ogihara, and T Hata, and M Nakamaru, and H Mikami, and A Maruyama, and Y Oakada, and Y Kumahara
Blood pressure response, but not adverse event incidence, correlates with dose of angiotensin II antagonist.
June 2001, Journal of hypertension. Supplement : official journal of the International Society of Hypertension,
T Ogihara, and T Hata, and M Nakamaru, and H Mikami, and A Maruyama, and Y Oakada, and Y Kumahara
Cerebroventricular infusion of angiotensin antagonist does not influence hypertensive response to blood-borne angiotensin II.
December 1985, Brain research,
T Ogihara, and T Hata, and M Nakamaru, and H Mikami, and A Maruyama, and Y Oakada, and Y Kumahara
Renal hemodynamic response to an angiotensin II antagonist, eprosartan, in healthy men.
August 1997, Hypertension (Dallas, Tex. : 1979),
T Ogihara, and T Hata, and M Nakamaru, and H Mikami, and A Maruyama, and Y Oakada, and Y Kumahara
Association between angiotensinogen, angiotensin II receptor genes, and blood pressure response to an angiotensin-converting enzyme inhibitor.
February 2007, Circulation,
Copied contents to your clipboard!